[ BiomX raises $24M in Series A ]

BiomX has raised $24 million in Series A funding.

Founded in 2015, BiomX discovers and develops innovative microbiome therapeutics. The Company’s mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated.

The new financing will be used to advance its novel therapeutic pipeline towards clinical stages and to continue enhancing its proprietary microbiome modulation platform technologies.

Funding  Series A
Founded  2015
Country  Israel
City  /
Founder / CEO  Jonathan Solomon
Deal Size  $24M
Investors  OrbiMed
 SBI Japan-Israel Innovation Fund
  Mirae Asset Venture Investment
 Seventure Partners
 Takeda Ventures
 Johnson & Johnson Innovation
Previous Investors  /